Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events

Abstract Background Immune checkpoint inhibitors (ICI) have demonstrated remarkable efficacy as cancer therapeutics, however, their use remains limited due to the development of immune related adverse events (irAEs). Immune related enterocolitis (irEC) is among the most common severe irAEs leading t...

Full description

Bibliographic Details
Main Authors: Yousef R. Badran, Justine V. Cohen, Priscilla K. Brastianos, Aparna R. Parikh, Theodore S. Hong, Michael Dougan
Format: Article
Language:English
Published: BMJ Publishing Group 2019-08-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Checkpoint inhibitor
PD-1
CTLA-4
TNFα
Infliximab
Immune related enterocolitis
Online Access:http://link.springer.com/article/10.1186/s40425-019-0711-0

Internet

http://link.springer.com/article/10.1186/s40425-019-0711-0

Similar Items